Phaseline

Companies › pharmaand

pharmaand: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rucaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus …Dec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04624178RucaparibPhase 2LeiomyosarcomaOncologyNov 2026
NCT02873962RucaparibPhase 2Peritoneal CancerOncologyJan 2027
NCT04253262RucaparibPhase 1Metastatic Castration-resistant Prostate CancerOncologyJan 2027
NCT02678182RucaparibPhase 2Adenocarcinoma of the OesophagusOncologyJun 2027
NCT03522246RucaparibPhase 3Epithelial Ovarian CancerOncologyDec 2030

Targets

PARP1 (1) PARP3 (1) PARP2 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Boryung Pharmaceutical Daewoong Pharmaceutical Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene Impact Therapeutics

Companies built like this

Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) Epizyme CanariaBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.